Fusion Pharmaceuticals Performance
| FUSNDelisted Stock | USD 3.75 0.33 8.09% |
The firm shows a Beta (market volatility) of 0.64, which means possible diversification benefits within a given portfolio. As returns on the market increase, Fusion Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Fusion Pharmaceuticals is expected to be smaller as well. Fusion Pharmaceuticals right now shows a risk of 0.0%. Please confirm Fusion Pharmaceuticals skewness, and the relationship between the value at risk and day median price , to decide if Fusion Pharmaceuticals will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Fusion Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy basic indicators, Fusion Pharmaceuticals is not utilizing all of its potentials. The latest stock price disarray, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 44.3 M |
Fusion |
Fusion Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 375.00 in Fusion Pharmaceuticals on September 1, 2024 and sell it today you would earn a total of 0.00 from holding Fusion Pharmaceuticals or generate 0.0% return on investment over 90 days. Fusion Pharmaceuticals is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Fusion, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Fusion Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Fusion Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Fusion Pharmaceuticals, and traders can use it to determine the average amount a Fusion Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| FUSN |
Based on monthly moving average Fusion Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Fusion Pharmaceuticals by adding Fusion Pharmaceuticals to a well-diversified portfolio.
Fusion Pharmaceuticals Fundamentals Growth
Fusion Stock prices reflect investors' perceptions of the future prospects and financial health of Fusion Pharmaceuticals, and Fusion Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Fusion Stock performance.
| Return On Equity | -0.47 | |||
| Return On Asset | -0.23 | |||
| Operating Margin | (54.04) % | |||
| Current Valuation | 1.69 B | |||
| Shares Outstanding | 85.06 M | |||
| Price To Book | 8.13 X | |||
| Price To Sales | 874.50 X | |||
| Revenue | 2.07 M | |||
| EBITDA | (97.89 M) | |||
| Cash And Equivalents | 198.42 M | |||
| Cash Per Share | 4.57 X | |||
| Total Debt | 50.33 M | |||
| Debt To Equity | 0.08 % | |||
| Book Value Per Share | 2.85 X | |||
| Cash Flow From Operations | (81.8 M) | |||
| Earnings Per Share | (1.40) X | |||
| Total Asset | 285.84 M | |||
| Retained Earnings | (376.76 M) | |||
About Fusion Pharmaceuticals Performance
By examining Fusion Pharmaceuticals' fundamental ratios, stakeholders can obtain critical insights into Fusion Pharmaceuticals' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Fusion Pharmaceuticals is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada. Fusion Pharmaceuticals is traded on NASDAQ Exchange in the United States.Things to note about Fusion Pharmaceuticals performance evaluation
Checking the ongoing alerts about Fusion Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Fusion Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Fusion Pharmaceuticals is not yet fully synchronised with the market data | |
| Fusion Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 2.07 M. Net Loss for the year was (94.9 M) with loss before overhead, payroll, taxes, and interest of (57.43 M). | |
| Fusion Pharmaceuticals currently holds about 198.42 M in cash with (81.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.57, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 87.0% of the company shares are owned by institutional investors |
- Analyzing Fusion Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Fusion Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Fusion Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Fusion Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Fusion Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Fusion Pharmaceuticals' stock. These opinions can provide insight into Fusion Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Other Consideration for investing in Fusion Stock
If you are still planning to invest in Fusion Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Fusion Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |